Tech-Driven Drug Innovation
Artificial Intelligence Empowers Drug Screening and Process Development
New Peptide Sustained Release
Combined Drug-Device Development Technology
AI: Empower New Drug Discovery
Peptide Chips + AI: Empower New Drug Discovery
AI is revolutionizing drug discovery, speeding up development and boosting efficiency. Hybio, in strategic collaboration, leverages peptide chips to detect peptide-target receptor interactions, building a proprietary database. This fuels machine learning for large-scale training; reinforcement learning optimizes design to generate target-specific peptide molecules. Applied to metabolic peptide drug discovery, its GLP-1R/GIPR/GCGR triple agonist project advancing to the preclinical candidate stage.
Application results
-
Peptide microarray data + AI reinforcement learning -
Supports linear/cyclic peptide probes
-
Enables non-natural amino acid introduction
-
Integrates wet experiments for rapid iterative screening of new peptides
-
In vivo POC (proof of concept) verification completed
Ai-Powered Process Development
Peptide Process Development Assistant
Hybio Co-developed with partners, leveraging 20+ years of digitized process data (100,000+ historical processes) in a private database. Enables intelligent matching of molecular structures with internal/external patent databases (CAS, Reaxys) and dynamic process optimization via QbD.
Application results
-
Process development cycle cut by 50%+ (Case: 5-step API synthesis: 18 months → 8.2 months)
-
Production success rate up to 90% (vs. ~70% with traditional methods)
-
Knowledge retrieval 20x faster (3 minutes vs. 2 weeks for traditional teams)
New Gel Storage Technology
-
Easy administration: Simplifies injection, enhances clinical/user convenience.
-
Balances rapid/sustained release, optimizes drug duration (controlled release: days to months).
-
Versatile: Suitable for multiple drug types.
-
Safe: Based on natural lipids, reducing toxic side effects.
-
Standardized production: Facilitates scalability, quality control & industrialization.
GLP-1 Drug In-Situ Gel Preparations
Enhanced patient compliance
Monthly long-acting formulations reduce injection frequency vs. daily/weekly dosing, lowering burden and improving adherence.
Steady drug exposure
In-situ gel sustained-release avoids "peak-trough effect," maintaining stable concentrations to reduce glucose fluctuations.
Reduced adverse reactions
Gradual concentration increase minimizes GLP-1RA gastrointestinal side effects (nausea, vomiting, diarrhea), improving tolerability.
Complex Peptide + Injection Pen Medical Device Combination
-
First US-approved generic of GLP-1 daily liraglutide injection. This combination medical device includes a pre-filled pen with cartridge packaging, enabling 30 single-dose administrations per pen.
-
Hybio’s R&D in injection pen combination medical devices.
Comprehensive Device Testing & Validation
-
Performance: Dose accuracy/repeatability, delivery force, flow rate, leakage, drop/durability (multi-injection simulation), environmental adaptability (temperature/humidity).
-
Safety: Needle sharpness/penetration force, sleeve activation reliability, biocompatibility (ISO 10993), sterility (where applicable).
-
Usability: Ensuring safe, effective operation for users (especially patients).
International Registration Experience
•Develop regulatory-compliant registration pathways for target markets (NMPA, FDA, CE, etc.).
Respond to regulatory inquiries through to marketing authorisation.
Large-scale Production Ability
Hybio Pingshan Base: Swiss Mikron automatic injection pen assembly line enables large-scale production.
